APC
DRUG

Aspire Private Capital’s Bright Minds Biosciences DRUG Stock Holding History

Aspire Private Capital’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$117 – 292
2024
Q3 		$117 Hold
100
– – ﹤0.01% 652
2024
Q2 		$108 Hold
100
– – ﹤0.01% 667
2024
Q1 		$120 Hold
100
– – ﹤0.01% 699
2023
Q4 		$143 Hold
100
– – ﹤0.01% 680
2023
Q3 		$160 Buy
+100
New +$267 ﹤0.01% 676
2023
Q2 		– Sell
-100
Closed -$220 – 678
2023
Q1 		$220 Hold
100
– – ﹤0.01% 621
2022
Q4 		$370 Hold
100
– – ﹤0.01% 608
2022
Q3 		$1K Hold
100
– – ﹤0.01% 552
2022
Q2 		$0 Hold
100
– – ﹤0.01% 614
2022
Q1 		$1K Hold
100
– – ﹤0.01% 538
2021
Q4 		$2K Buy
+100
New +$2.23K ﹤0.01% 511

Other funds holding DRUG

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Aspire Private Capital's DRUG Position: Q4 2024 in Review

Aspire Private Capital sold out of Bright Minds Biosciences (DRUG) in Q4 2024, closing a stake of 100 shares — an estimated $117 sold.

Aspire Private Capital first reported a position in DRUG in Q4 2021 and held it in 11 quarters. The position peaked at $2K in Q4 2021. 31 funds tracked by Wall St. Rank hold DRUG as of Q4 2024.

  • Aspire Private Capital reported no remaining Bright Minds Biosciences position as of Q4 2024 after selling out during the quarter.
  • Aspire Private Capital sold 100 Bright Minds Biosciences shares in Q4 2024, an estimated $117.
  • Aspire Private Capital first reported a position in Bright Minds Biosciences in Q4 2021 and held it in 11 quarters.
  • Aspire Private Capital's Bright Minds Biosciences position peaked at $2K in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.